A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma

NCT02954796 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

27

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Multiple Myeloma

Interventions

DRUG: SGN-CD352A

Sponsor

Seagen Inc.